CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $702.93 million. The enterprise value is $672.26 million.
| Market Cap | 702.93M |
| Enterprise Value | 672.26M |
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 78.45 million shares outstanding. The number of shares has increased by 39.80% in one year.
| Current Share Class | 78.45M |
| Shares Outstanding | 78.45M |
| Shares Change (YoY) | +39.80% |
| Shares Change (QoQ) | -0.99% |
| Owned by Insiders (%) | 7.17% |
| Owned by Institutions (%) | 45.69% |
| Float | 66.55M |
Valuation Ratios
The trailing PE ratio is 4.23 and the forward PE ratio is 61.08.
| PE Ratio | 4.23 |
| Forward PE | 61.08 |
| PS Ratio | 1.76 |
| Forward PS | 2.55 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 18.37 |
| P/FCF Ratio | 3.61 |
| P/OCF Ratio | 3.56 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.94, with an EV/FCF ratio of 3.45.
| EV / Earnings | 3.73 |
| EV / Sales | 1.68 |
| EV / EBITDA | 2.94 |
| EV / EBIT | 3.30 |
| EV / FCF | 3.45 |
Financial Position
The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.34.
| Current Ratio | 2.98 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 0.64 |
| Debt / FCF | 0.76 |
| Interest Coverage | 73.28 |
Financial Efficiency
Return on equity (ROE) is 65.59% and return on invested capital (ROIC) is 49.12%.
| Return on Equity (ROE) | 65.59% |
| Return on Assets (ROA) | 26.40% |
| Return on Invested Capital (ROIC) | 49.12% |
| Return on Capital Employed (ROCE) | 29.68% |
| Weighted Average Cost of Capital (WACC) | 10.52% |
| Revenue Per Employee | $2.09M |
| Profits Per Employee | $942,534 |
| Employee Count | 191 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, CorMedix has paid $4.01 million in taxes.
| Income Tax | 4.01M |
| Effective Tax Rate | 2.16% |
Stock Price Statistics
The stock price has decreased by -39.83% in the last 52 weeks. The beta is 1.47, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -39.83% |
| 50-Day Moving Average | 7.79 |
| 200-Day Moving Average | 9.31 |
| Relative Strength Index (RSI) | 68.32 |
| Average Volume (20 Days) | 1,493,891 |
Short Selling Information
The latest short interest is 15.54 million, so 19.81% of the outstanding shares have been sold short.
| Short Interest | 15.54M |
| Short Previous Month | 16.22M |
| Short % of Shares Out | 19.81% |
| Short % of Float | 23.35% |
| Short Ratio (days to cover) | 12.73 |
Income Statement
In the last 12 months, CorMedix had revenue of $400.05 million and earned $180.02 million in profits. Earnings per share was $2.12.
| Revenue | 400.05M |
| Gross Profit | 367.51M |
| Operating Income | 203.87M |
| Pretax Income | 185.02M |
| Net Income | 180.02M |
| EBITDA | 228.81M |
| EBIT | 203.87M |
| Earnings Per Share (EPS) | $2.12 |
Balance Sheet
The company has $178.09 million in cash and $147.42 million in debt, with a net cash position of $30.67 million or $0.39 per share.
| Cash & Cash Equivalents | 178.09M |
| Total Debt | 147.42M |
| Net Cash | 30.67M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 437.05M |
| Book Value Per Share | 5.57 |
| Working Capital | 254.34M |
Cash Flow
In the last 12 months, operating cash flow was $197.69 million and capital expenditures -$2.98 million, giving a free cash flow of $194.71 million.
| Operating Cash Flow | 197.69M |
| Capital Expenditures | -2.98M |
| Depreciation & Amortization | 24.93M |
| Net Borrowing | 149.68M |
| Free Cash Flow | 194.71M |
| FCF Per Share | $2.48 |
Margins
Gross margin is 91.86%, with operating and profit margins of 50.96% and 45.25%.
| Gross Margin | 91.86% |
| Operating Margin | 50.96% |
| Pretax Margin | 46.25% |
| Profit Margin | 45.25% |
| EBITDA Margin | 57.19% |
| EBIT Margin | 50.96% |
| FCF Margin | 48.67% |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.80% |
| Shareholder Yield | -39.80% |
| Earnings Yield | 25.61% |
| FCF Yield | 27.70% |
Analyst Forecast
The average price target for CorMedix is $15.33, which is 71.09% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.33 |
| Price Target Difference | 71.09% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 3.50% |
| EPS Growth Forecast (3Y) | -8.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
CorMedix has an Altman Z-Score of 2.69 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.69 |
| Piotroski F-Score | 5 |